Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Corporation

Insiders have been trading these 5 stocks: (($BSX)), (($LITE)), (($MCHP)), (($ABR)) and (($JMIA)). Here is a breakdown of their recent trades and t...

Boston Scientific, Lumentum, Microchip, Arbor, Jumia Moves

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Boston Scientific today and set a price target of $75.00. According to TipRanks, Bie...

Wells Fargo Keeps Their Buy Rating on Boston Scientific (BSX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Design Therapeutics (DSGN), Pro Medicus Limited (PMCUF) and Bosto...

Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN), Pro Medicus Limited (OtherPMCUF) and Boston Scientific (BSX)

In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Boston Scientific, with a price target of $100.00. According t...

Jefferies Sticks to Their Buy Rating for Boston Scientific (BSX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Boston Scientific (BSX), Context Therapeutics (CNTX)...

Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Context Therapeutics (CNTX)

Three names are expected to have strong setups this week: Zeta Global ($ZETA), Boston Scientific ($BSX), and Summit Therapeutics ($SMMT). Each stoc...

3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22

Investors will find the top stock market stories for Monday ready to go in our daily wrap-up.


Morning News Wrap-Up, 5/18/26: Today’s Biggest Stock Market Stories!

Boston Scientific’s ($BSX) stock is up 4% after the medical device maker announced an accelerated $2 billion stock buyback program. Boston Scientif...

Here’s Why Boston Scientific’s Stock (BSX) Is Surging Today

Boston Scientific ( ($BSX) ) has shared an announcement. On May 18, 2026, Boston Scientific said it invested $1.5 billion for roughly a 34% non‑vot...

Boston Scientific Invests in MiRus to Expand TAVR Portfolio

The latest update is out from Boston Scientific ( ($BSX) ). Boston Scientific on May 18, 2026, entered into a $2 billion accelerated share repurcha...

Boston Scientific Launches $2 Billion Accelerated Share Repurchase

Boston Scientific ($BSX) announced an update on their ongoing clinical study. Boston Scientific’s new update covers its observational study “A DirE...

Boston Scientific’s Chronic Pain Study Update: What Investors Should Watch

Blackstone Minerals Ltd ( ($AU:BSX) ) just unveiled an announcement. Blackstone Minerals has issued 654,322 fully paid ordinary shares and notified...

Blackstone Minerals Clears Regulatory Path for On-Sale of Newly Issued Shares

The latest update is out from Blackstone Minerals Ltd ( ($AU:BSX) ). Blackstone Minerals Ltd has applied to the ASX for quotation of 654,322 new or...

Blackstone Minerals Seeks ASX Quotation for Additional Ordinary Shares

Boston Scientific ( ($BSX) ) just unveiled an update. Boston Scientific held its 2026 annual meeting of stockholders on April 30, 2026, in a virtua...

Boston Scientific Shareholders Approve Directors and Governance Changes

FST Corp ( ($KBSX) ) has shared an announcement. On May 5, 2026, FST Corp. reported unaudited condensed consolidated financial results for the quar...

FST Corp. Swings to Operating Profit on Higher Q1 2026 Revenue

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC) and Boston Scientific (BSX) with bul...

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Boston Scientific (BSX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Boston Scientific (BSX), Resmed (RMD) and HCA Health...

Market Cap	$84.44B	P/E Ratio	17.07
52W High	$109.50	52W Low	$52.52
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	63.3%	52W Position	9.1%
Overall Score	41	Value Score	45
Quality Score	71	Technical Score	9

EPS Current Est	$3.38	EPS Next Est	$3.75
EPS Growth Est	+10.9%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BSX	$57.69	-0.16%	5.22M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BSX	$57.69	-0.2%	5.22M
3
4
5
6

BSX

BSX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Boston Scientific Corporation Data in Excel

Get Boston Scientific Corporation Data in Excel